Our study provides the first prospective, preliminary, evidence on the impact of ICIs therapy for melanoma on testicular function in men, demonstrating overall modest effects on sperm output and function with raised serum FSH due to one man developing severe spermatogenic damage (azoospermia) due to presumed autoimmune orchitis. The gene discussed is BRD2; the disease is melanoma.